drugset

drugset / Trial / NCT00559117

A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer

NCT00559117 ↗

Phase 1 Unknown 48 enrolled Vascular Biogenics Ltd. operating as VBL Therapeutics

NaSingle-groupOpen-labelTreatment

Summary

Aim of the study is to evaluate the safety and find the maximal tolerated dose of VB-111 in Patients with Advanced Metastatic Cancer

Timeline

Start: 2007-11
Primary completion: 2015-06
Completion: 2015-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VB-111	Other / unclassified	—	Intravenous

Indications